Bayer extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease
The Pharma Data
SEPTEMBER 29, 2021
In 2017, an alarming 1.2 The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. million people died from chronic renal disorder worldwide.
Let's personalize your content